Tigecycline to treat Stenotrophomonas maltophilia ventilator-associated pneumonia in a trauma intensive care unit as a result of a drug shortage: A case series.
Adult
Anti-Bacterial Agents
/ therapeutic use
Gram-Negative Bacterial Infections
/ drug therapy
Humans
Intensive Care Units
Male
Pneumonia, Ventilator-Associated
/ drug therapy
Stenotrophomonas maltophilia
/ drug effects
Tigecycline
/ therapeutic use
Trimethoprim, Sulfamethoxazole Drug Combination
/ supply & distribution
Wounds and Injuries
/ therapy
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
27
12
2019
revised:
10
03
2020
accepted:
13
04
2020
pubmed:
15
5
2020
medline:
13
4
2021
entrez:
15
5
2020
Statut:
ppublish
Résumé
Stenotrophomonas maltophilia is an intrinsically multidrug-resistant (MDR) organism which commonly presents as a respiratory tract infection. S. maltophilia is typically treated with high-dose sulfamethoxazole/trimethoprim (SMX/TMP). However, SMX/TMP and other treatment options for S. maltophilia can be limited because of resistance, allergy, adverse events or unavailability of the drug; use of novel agents may be necessary to adequately treat this MDR infection and overcome these limitations. This small case series describes two patients who underwent treatment with tigecycline for ventilator-associated pneumonia (VAP) caused by S. maltophilia after admission to a trauma intensive care unit. At the time of admission for the two reported patients, a national drug shortage of intravenous (IV) SMX/TMP prevented its use. Tigecycline was chosen as a novel agent to treat S. maltophilia VAP based on culture and susceptibility data, and it was used successfully. Both patients showed clinical signs of improvement with eventual cure and discharge from the hospital after treatment with tigecycline, and one patient demonstrated confirmed microbiological cure with a negative repeat bronchoscopic bronchoalveolar lavage (BAL). To our knowledge, this small case series is the first documentation of utilizing tigecycline to treat S. maltophilia VAP in the United States. Although it likely should not be considered as a first-line agent, tigecycline proved to be an effective treatment option in the two cases described in the setting of a national drug shortage of the drug of choice.
Substances chimiques
Anti-Bacterial Agents
0
Tigecycline
70JE2N95KR
Trimethoprim, Sulfamethoxazole Drug Combination
8064-90-2
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
836-839Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Chang YT, Lin CY, Chen YH, Hsueh PR. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol. 2015;6:893.
Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother. 2010;54(6):2735-2737.
Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis. 2001;32(Suppl 2):S104-113.
Looney WJ, Narita M, Mühlemann K Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009;9(5):312-323.
Brooke JS Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25(1):2-41.
Fedler KA, Biedenbach DJ, Jones RN. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn Microbiol Infect Dis. 2006;56(4):427-436.
Mueller EW, Croce MA, Boucher BA, et al. Repeat bronchoalveolar lavage to guide antibiotic duration for ventilator-associated pneumonia. J Trauma. 2007;63(6):1329-1337; discussion 1337.
Magnotti LJ, Croce MA, Zarzaur BL, et al. Causative pathogen dictates optimal duration of antimicrobial therapy for ventilator-associated pneumonia in trauma patients. J Am Coll Surg. 2011;212(4):476-484; discussion 484-476.
Blanquer D, De Otero J, Padilla E, et al. Tigecycline for treatment of nosocomial-acquired pneumonia possibly caused by multi-drug resistant strains of Stenotrophomonas maltophilia. J Chemother. 2008;20(6):761-763.
Wu Y, Shao Z. High-dosage tigecycline for Stenotrophomonas maltophilia bacteremia. Chin Med J (Engl). 2014;127(17):3199.
Belvisi V, Fabietti P, Del Borgo C, et al. Successful treatment of Stenotrophomonas maltophilia soft tissue infection with tigecycline: a case report. J Chemother. 2009;21(3):367-368.
Tekçe YT, Erbay A, Cabadak H, Sen S. Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections. J Chemother. 2012;24(3):150-154.
Sharpe JP, Magnotti LJ, Weinberg JA, et al. Adherence to an established diagnostic threshold for ventilator-associated pneumonia contributes to low false-negative rates in trauma patients. J Trauma Acute Care Surg. 2015;78(3):468-474; discussion 473-464.
Swanson JM, Connor KA, Magnotti LJ, et al. Resolution of clinical and laboratory abnormalities after diagnosis of ventilator-associated pneumonia in trauma patients. Surg Infect (Larchmt). 2013;14(1):49-55.
Wood GC, Hanes SD, Boucher BA, Croce MA, Fabian TC. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Intensive Care Med. 2003;29(11):2072-2076.
Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. Clin Infect Dis. 2002;34(11):1425-1430.
Wood GC, Underwood EL, Croce MA, Swanson JM, Fabian TC. Treatment of recurrent Stenotrophomonas maltophilia ventilator-associated pneumonia with doxycycline and aerosolized colistin. Ann Pharmacother. 2010;44(10):1665-1668.
Czosnowski QA, Wood GC, Magnotti LJ, et al. Clinical and microbiologic outcomes in trauma patients treated for Stenotrophomonas maltophilia ventilator-associated pneumonia. Pharmacotherapy. 2011;31(4):338-345.
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Susceptibility Tests. 13th ed. CLSI Standard M02. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
Wei C, Ni W, Cai X, Zhao J, Cui J. Evaluation of trimethoprim/sulfamethoxazole (SXT), minocycline, tigecycline, moxifloxacin, and ceftazidime alone and in combinations for SXT-susceptible and SXT-resistant Stenotrophomonas maltophilia by in vitro time-kill experiments. PLoS ONE. 2016;11(3):e0152132.
Wei C, Ni W, Cai X, Cui J. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia. Infect Dis (Lond). 2015;47:846-851.
Food and Drug Administration (FDA). FDA drug safety communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics
Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66(9):1963-1971.
Gong J, Su D, Shang J, et al. Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: A meta-analysis. Medicine (Baltimore). 2019;98(38):e17091.